01:49 , Mar 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
23:47 , Mar 21, 2019 |  BC Week In Review  |  Company News

Novo submits semaglutide applications for CV risk reduction

Novo Nordisk submitted an NDA to FDA for oral semaglutide as an adjunct to diet and exercise to improve blood sugar in Type II diabetics. The company used a Priority Review voucher for the application....
18:02 , Mar 13, 2019 |  BC Innovations  |  Distillery Therapeutics

A PYY-IgG conjugate for obesity

DISEASE CATEGORY: Endocrine/Metabolic INDICATION: Obesity Mouse and non-human primate studies suggest a PYY-IgG conjugate could help treat obesity. The fusion protein consists of a 33-amino acid PYY fragment that promotes satiation linked to an IgG...
21:17 , Mar 5, 2019 |  BC Extra  |  Company News

Intarcia licenses Numab's autoimmune therapy

Ahead of an NDA resubmission for its Type II diabetes therapy, Intarcia exercised an option to license from Numab exclusive, worldwide rights to autoimmune disorder therapy, ND016. ND016 is a trispecific antibody fragment that blocks...
03:03 , Feb 15, 2019 |  BC Innovations  |  Tools & Techniques

Heartening predictors in diabetes

New biomarkers of cardiovascular risk could relieve a decade-old bottleneck for diabetes drug development, but validating them will require companies to invest in strategic trial designs, and public and private stakeholders to pool thinking. As...
23:25 , Feb 13, 2019 |  BC Extra  |  Preclinical News

Modifying adult human cells to produce insulin in situ

A University of Geneva team has expanded the strategies for replenishing insulin-producing cells in Type I diabetics by reprogramming human non-insulin-producing pancreatic islet cells, such as α cells, to adopt β cell properties. Pancreatic islet...
17:29 , Jan 11, 2019 |  BC Week In Review  |  Financial News

Suzhou-based BrightGene raises pre-IPO round

BrightGene Bio-Medical Technology Co. Ltd. (Suzhou, China) raised RMB550 million ($80.3 million) in a venture round on Jan. 7. The company described the funding as a "pre-IPO round," but did not immediately respond to an...
20:23 , Jan 7, 2019 |  BC Extra  |  Financial News

Suzhou-based BrightGene raises pre-IPO round

BrightGene Bio-Medical Technology Co. Ltd. (Suzhou, China) raised RMB550 million ($80.3 million) in a venture round. The company described the funding as a "pre-IPO round," but did not immediately respond to an inquiry about its...
13:43 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Endocrine/metabolic

INDICATION: Obesity Cell culture, mouse and non-human primate (NHP) studies suggest inhibiting the GIP receptor alone or in combination with GLP-1R agonists could help treat obesity. In a mouse model of diet-induced obesity, a mouse...
19:30 , Dec 21, 2018 |  BC Week In Review  |  Company News

CSPC gains Chinese rights to I-Mab's GLP-1

TG103, a long-acting glucagon-like peptide-1 (GLP-1), is in Phase I testing in Germany. I-Mab Biopharma, Shanghai, China  CSPC Pharmaceutical Group Ltd. (HKSE:1093), Hong Kong, China  Business: Endocrine/Metabolic  I-Mab Biopharma (Shanghai, China) granted CSPC Pharmaceutical Group...